Technical analysis is a method used to predict future price movements of stocks based on their historical trading data. It involves the examination of various technical indicators, such as RSI, ADX, MACD, ROC, STOCHRSI, and WILLR, to identify potential trends and patterns in stock prices. One company that traders and investors may consider applying technical analysis to is Axsome Therapeutics Inc (AXSM).

The RSI (Relative Strength Index) is a momentum oscillator that measures the speed and change of price movements. It is often used to identify overbought or oversold conditions in a stock. When the RSI value is above 70, it indicates overbought conditions, and when it is below 30, it suggests oversold conditions. Traders can use this indicator to make decisions on whether to buy or sell Axsome Therapeutics Inc stock.

Axsome Therapeutics  (AXSM) Technical Analysis

Learn about the technical analysis indicators for Axsome Therapeutics Inc (AXSM) stock including RSI, ADX, MACD, ROC, STOCHRSI, and WILLR. Understand the performance of AXSM stock through these indicators. Stay informed and make better investment decisions.

Technical Analysis of Axsome Therapeutics Inc (AXSM) Stock - RSI, ADX, MACD, ROC, STOCHRSI, WILLR

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that is in Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial of for treating attention-deficit/hyperactivity disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Axsome Therapeutics 

NASDAQ

This suggests that the technical indicators do not strongly favor either a buying or selling stance. In such cases, investors may need to rely on additional fundamental or market analysis to make a well-informed decision.

Balanced or Uncertain

MACD

WILLR

STOCHRSI

Free

is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.

Name	Value	Action	infoPnL (10y)
auto_graphRSI	76.55	Sell	-
auto_graphMACD	12.22	Neutral	4.3%
auto_graphCCI	129.51	Sell	109.7%
auto_graphADX	56.25	Neutral	0.8%
auto_graphATR	7.63	Buy	-
auto_graphWILLR	-3.78	Sell	51.6%
auto_graphROC	27.49	Neutral	9.0%
auto_graphSTOCHRSI	65.40	Neutral	133.2%

Buy	1	-87.50%
Hold	4	-50.00%
Sell	3	-62.50%

Trendlines, Support and Resistance

Welcome to Stocklytics

Technical Indicators

Indicator Ratings

Balanced or Uncertain

Axsome Therapeutics (AXSM) Technical Analysis

Keep an eye on Axsome Therapeutics

Frequently Asked Questions

What are the technical signals for Axsome Therapeutics (AXSM) stock based on the last 30 days?

Take Your Investments to a Whole New Level